Smoking cessation

Two New Peer-Reviewed Studies Exploring Tobacco Cessation Digital Clinic Quit Genius Find That It Increases Smokers' Motivation to Quit

Retrieved on: 
Tuesday, November 30, 2021
Motivation, CEO, Smoking, Tobacco, Solution, MAT, Smoking cessation, Evidence-based practice, Workplace, Research, GLOBE, Observational study, Smoker, Opioid addiction treatment in United States prisons, Quit, Public health, Pharmacy, Imperial College London, Privacy, Method, Pharmaceutical industry, Medical device

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quit Genius , the worlds first digital clinic for treating multiple addictions, announced today that two new peer-reviewed studies have found that the Quit Genius tobacco cessation program increases smokers motivation to quit, potentially leading to higher quit rates.

Key Points: 
  • NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quit Genius , the worlds first digital clinic for treating multiple addictions, announced today that two new peer-reviewed studies have found that the Quit Genius tobacco cessation program increases smokers motivation to quit, potentially leading to higher quit rates.
  • The study showed that Quit Genius positively impacted self-efficacy and motivation to quit, which are both crucial psychological factors involved in quitting smoking.
  • The average success rate for people in the Quit Genius tobacco program is 52 percent, far higher than traditional methods.
  • Quit Genius is the world's first digital clinic for treating tobacco, alcohol and opioid addictions.

Global Transdermal Drug Delivery Market, Technology and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 29, 2021
Pharmaceutical, Health, Medical Supplies, Blood, Skin, Parkinson's disease, Drug delivery, Birth, Angina, Nanoparticle, Hormone replacement therapy, Lists of diseases, Smoking cessation, Pain, Pharmaceutical industry

The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.
  • This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous and transmucosal routes.
  • Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers.

Ambetter of Illinois Health Plan Insured by Celtic Insurance Company Offers Health Insurance in 14 Counties Across Illinois

Retrieved on: 
Thursday, November 18, 2021
Health insurance marketplace, Blood pressure, CEO, Nausea, United States Public Health Service, Diabetes, Hearing, Diagnosis, Health, HSA, Vitamin, Humidifier, Smoking cessation, Program, COVID-19, Centene Corporation, Allergy, Health insurance

Ambetterof Illinois ,insured by Celtic Insurance Company, is offering affordable health insurance options in 14 counties across Illinois through the federal Health Insurance Marketplace.

Key Points: 
  • Ambetterof Illinois ,insured by Celtic Insurance Company, is offering affordable health insurance options in 14 counties across Illinois through the federal Health Insurance Marketplace.
  • "Ambetter of Illinois has a variety of plans and benefits, so more people have access to affordable, high quality health insurance options."
  • Ambetter of Illinois and Walgreens are improving the affordability of health and wellness products for members in Illinois.
  • Below is a list of counties in which Ambetter of Illinois will be offered:

Baptist Announces Mid-South Miracle Initiative

Retrieved on: 
Tuesday, November 16, 2021
Health, Quality of life, Smoking cessation, National, Lung cancer, Cancer, Patient-Centered Outcomes Research Institute, Disease, NCI, Research, NEA Baptist Memorial Hospital, Lung cancer screening, National Cancer Institute, GLOBE, Diagnosis, BCC, Pathology, Genetic counseling, Patient, CT, Adult, Pharmaceutical industry, Medical imaging

Memphis, Tennessee, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Baptist Cancer Center in Memphis announced a multifaceted initiative called the Mid-South Miracle aimed at reducing lung cancer deaths in the Mid-South by 25% by 2030.

Key Points: 
  • Memphis, Tennessee, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Baptist Cancer Center in Memphis announced a multifaceted initiative called the Mid-South Miracle aimed at reducing lung cancer deaths in the Mid-South by 25% by 2030.
  • We have spent years developing the critical components of the Mid-South Miracle, and I am excited to see it realized, said Dr. Raymond Osarogiagbon, chief scientist and director of Baptist Cancer Centers Multidisciplinary Thoracic Oncology Program.
  • The Patient-Centered Outcomes Research Institute awarded Baptist Cancer Center $2.5 million to evaluate the effectiveness and success of multidisciplinary care for lung cancer patients.
  • Baptist Cancer Center provides world-class cancer care close to home throughout Baptist Memorial Health Cares tristate service area of Arkansas, Mississippi and Tennessee.

New INNCO Dossier Raises Major Questions On Anti-vaping Stance

Retrieved on: 
Tuesday, November 9, 2021
People, Smoking cessation, Climate change, WHO, FCTC, WHO Framework Convention on Tobacco Control, First Nations in Ontario, Government, Department, Research, Department of Health and Social Care, Policy, Completeness, Conference, Social work, NHS, Framework convention, COP9, Smoking, United Nations, Tobacco, Bloomberg, Guidelines International Network, Nicotine

LONDON, Nov. 9, 2021 /PRNewswire/ -- A new report by the International Network of Nicotine Consumer Organisations (INNCO), raises major questions on the anti-vaping arguments of the WHO, and American businessman Mike Bloomberg.

Key Points: 
  • LONDON, Nov. 9, 2021 /PRNewswire/ -- A new report by the International Network of Nicotine Consumer Organisations (INNCO), raises major questions on the anti-vaping arguments of the WHO, and American businessman Mike Bloomberg.
  • WHO and Bloomberg have made clear their opposition to safer nicotine alternatives despite growing evidence of lower harm and efficacy for smoking cessation.
  • In July, the two parties restated their joint position at the launch of the WHO's 8thReport on the Global Tobacco Epidemic: Addressing New and Emerging Products.
  • The dossier, Bloomberg, the WHO and the Vaping Misinfodemic , contains statements and evidence from wide ranging sources including healthcare experts, leading academics, politicians, respected journalists and research organisations regarding safer nicotine alternatives to smoking.

Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 8, 2021
NDA, Smoking cessation, NMDA, Central nervous system disease, ACCORD, Therapy, Clinical trial, Depression, Food, Chemistry, Smoking, Webcast, Review, DCC, Safety, Food and Drug Administration, Agitation, AXS-05, Research, Travel, Annual general meeting, GEMINI, GLOBE, New Drug Application, Prescription Drug User Fee Act, Narcolepsy, Patient, FDA, Migraine, American College of Neuropsychopharmacology, G&A, AD, MDD, SYMPHONY, NASDAQ, Breakthrough therapy, R, Fibromyalgia, Reboxetine, ID, Central nervous system, American College, Lists of diseases, Bupropion, Priority review, MD, ASCEND, CNS, Company, Awareness, PDUFA, Physician, CMC, Pharmaceutical industry, Risk management

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2021.
  • Cash: At September 30, 2021, Axsome had $114.6 million of cash compared to $183.9 million at December 31, 2020.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2021 financial results as well as to provide a corporate update.
  • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options.

Smoking Cessation and Nicotine Addiction Pipeline Market Report 2021 Featuring Achieve LifeSciences, NFL Biosciences, & Axsome Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 5, 2021
Tobacco, Retail, Health, Other Health, News, Clinical trial, Mergers and acquisitions, II, Therapy, Nicotine, NFL, Phase, Acquisition, Smoking, Drug development, Smoking cessation, Discovery, Tobacco, Pharmaceutical industry

The "Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation and Nicotine Deaddiction R&D.
  • Smoking Cessation and Nicotine Deaddiction: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage.

DGAP-News: ZeU Files Patent Allowing Multiple Permission Levels within a Document

Retrieved on: 
Tuesday, August 24, 2021
Ecosystem, Laika (EHR testing framework), IOT, CSE, DLT, Privacy, Dutch Healthcare Authority, Software, Smoking cessation, Literature, Transaction, Data management, Internet, CNSX, SMTP, EHR, Time, Cloud computing, ZeuS Panda, Electronic health record, OTC, Algorithm, Mula, Zeus Technology, Patent, Technology, Cryptocurrency, Online shopping

The patent for Permission-Based Multi-Level Encryption Scheme Document for Decentralized Storage covers elements already integrated into the Mula platform that will add IoT functionalities.

Key Points: 
  • The patent for Permission-Based Multi-Level Encryption Scheme Document for Decentralized Storage covers elements already integrated into the Mula platform that will add IoT functionalities.
  • This method makes use of symmetric and asymmetric (aka public-key encryption) encryption schemes as defined in the literature.
  • The strategy used in this method is to structure a document using blocks, such that each block can be encrypted independently using a symmetric key.
  • The symmetric key could be generated in a cryptographically-secured way and could be based on a random or pseudo-random seed for security purposes.

$13+ Bn Digital Therapeutics (DTx) Markets, 2026: Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation - ResearchAndMarkets.com

Retrieved on: 
Monday, August 16, 2021
Medical Devices, Hospitals, Diabetes, Cardiology, Practice Management, Other Health, Managed Care, General Health, Pharmaceutical, Health, MSD, Digital therapeutics, Single-frequency network, Substance Abuse, CRD, CVD, Awareness, Government, Diabetes, Conditional sentence, B2C, CAGR, Lists of diseases, Central nervous system disease, Smoking cessation, Lists of countries and territories, Medicine, Chronic Respiratory Disease, GI, Degenerative disease, Direct-to-consumer, Digital, Investment, Growth, Incidence, CNS, Health, Therapy, USD, Prevalence, Sales, Pharmaceutical industry

The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4%.

Key Points: 
  • The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4%.
  • The treatment/care-related applications segment accounted for the largest share of the digital therapeutics market in 2020.
  • Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications.
  • Factors such as the influx of new startups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Digital Therapeutics (DTx) Market Size to Reach USD 13.80 Billion by 2027 at a CAGR of 20.5% | Valuates Reports

Retrieved on: 
Monday, August 9, 2021
Smoking cessation, Investment, R, Diabetes, Software, USD, Adoption, CVD, Conditional sentence, Medication, Digital, Central nervous system, Therapy, Gaps, CNS, Cardiovascular disease, GID, Growth, Caregiver, Degenerative disease, Pharmacy, Patient, Medtech, Tablet, Respiratory disease, Prevalence, Intussusception (medical disorder), Physician, Medicine, Pharmaceutical industry, Health insurance

The global digital therapeutics market size was valued at USD 2.88 Billion in 2019 and is expected to reach USD 13.80 Billion by 2027 with aCAGR of 20.5%during the forecast period.

Key Points: 
  • The global digital therapeutics market size was valued at USD 2.88 Billion in 2019 and is expected to reach USD 13.80 Billion by 2027 with aCAGR of 20.5%during the forecast period.
  • Major factors driving the growth of the digital therapeutics market are:
    Digital therapeutics aids in the prevention, management, and treatment of medical disorders.
  • These factors are in turn expected to drive the growth of digital therapeutics market size.
  • Changing medical protocols, as well as the need to reduce healthcare costs, are driving an increase in digital therapeutics investments.